Clinical trials: Hematologic Disorders
Acute Myeloid Leukemia
Acute Myeloid Leukaemia (AML) Patients Undergoing Induction Chemotherapy
Fatigue, reduced quality of life and declines in physical function are common in patients undergoing chemotherapy for acute myeloid leukaemia (AML).
- Trial name
- NCT01170598
- Testing
- Exercise
- Where
- Canada
- Volunteers
- 35 people
- Sponsor
- Toronto Rehabilitation Institute
Myelogenous Leukemia, Chronic
Expanded Access Study With Peginterferon Alfa-2a (Pegasys) in Participants With Chronic Myelogenous Leukemia (CML)
This study will evaluate the efficacy, safety and tolerability of long-term use of peginterferon alfa-2a in participants with CML who have previously participated in peginterferon alfa-2a study ML16544 (NCT number not available)…
- Trial name
- NCT02736721
- Testing
- Peginterferon alfa-2a
- Where
- 5 sites in Germany
- Volunteers
- 41 people
- Sponsor
- Hoffmann-La Roche
Multiple Myeloma
Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Clinical Activity of GSK2857916
This study will assess the safety, pharmacokinetic (PK), pharmacodynamic (PD) and the therapeutic potential of GSK2857916 in subjects with multiple myeloma (MM) and lymphomas that express B cell maturation antigen (BCMA).
- Trial name
- NCT02064387
- Testing
- GSK2857916
- Where
- 9 sites in United States, Canada and 1 more
- Volunteers
- 79 people
- Sponsor
- GlaxoSmithKline
Iron-deficiency
Ferric Carboxymaltose to Improve Skeletal Muscle Metabolism in Heart Failure Patients With Functional Iron Deficiency
The purpose of this study is to better understand how body levels of iron affect the ability to exercise in patients with heart failure (HF).
- Trial name
- NCT03218384
- Testing
- Ferric Carboxymaltose, 31P MRS/MRI
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- NYU Langone Health
Classical Hodgkin Lymphoma, B-cell Non-Hodgkin Lymphoma
Pilot Study of Pembrolizumab Treatment for Disease Relapse After Allogeneic Stem Cell Transplantation
This pilot study has been designed to investigate the safety of pembrolizumab treatment for disease relapse following allogeneic stem cell transplant (alloSCT).
- Conditions
- Classical Hodgkin Lymphoma, B-cell Non-Hodgkin Lymphoma, Acute Myeloid Leukemia, Myelodysplastic Syndromes
- Trial name
- NCT02981914
- Testing
- Pembrolizumab
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Chicago
Multiple Myeloma, Advanced Solid Tumors
Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Participants With Normal Renal Function or Severe Renal Impairment
The purpose of this study is to characterize the single-dose pharmacokinetic (PK) parameters of ixazomib (MLN9708) in cancer participants with either normal renal function or severe renal impairment (RI), including participants…
- Trial name
- NCT01830816
- Testing
- Ixazomib
- Where
- 11 sites in United States, Canada
- Volunteers
- 41 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Hemophilia A
Rituximab to Treat Severe Hemophilia A
Hemophilia A is a serious blood clotting disorder caused by a lack of factor VIII, a specialized protein needed for normal blood clotting to occur.
- Trial name
- RICH (NCT00331006)
- Testing
- Rituximab
- Where
- 13 sites in United States
- Volunteers
- 23 people
- Sponsor
- Carelon Research
Sickle Cell Disease, Renal Function Disorder
Evaluation of the Impact of Renal Function on the Pharmacokinetics of SIKLOS ® (DARH)
The use of hydroxyurea in sickle cell disease patients with glomerular hyperfiltration and renal failure requires a specific monitoring and dose adjustment in order to remain within the therapeutic interval while limiting the…
- Trial name
- NCT02522104
- Testing
- Siklos
- Where
- France
- Volunteers
- 40 people
- Sponsor
- Theravia
Primary Immune Deficiency Disorders, Common Variable Immunodeficiency
A Study to Find Out How Safe and Effective Gammaplex® is in Young People With Primary Immunodeficiency
The main objective is to determine the efficacy of Gammaplex by measuring the number of serious acute bacterial infections during treatment with Gammaplex over a 12 month period.
- Conditions
- Primary Immune Deficiency Disorders, Common Variable Immunodeficiency, X-linked Agammaglobulinemia, Hyper-IgM Syndrome
- Trial name
- NCT01289847
- Testing
- Gammaplex
- Where
- 10 sites in United States, Chile and 1 more
- Volunteers
- 25 people
- Sponsor
- Bio Products Laboratory
Hematologic Malignancies
Chemotherapy Followed by Allogeneic Stem Cell Transplantation for Hematologic Malignancies
The purpose of this study is to determine disease-free survival, overall survival, time to progression, regimen-related toxicity and/or treatment-related mortality in patients with hematologic malignancies treated with…
- Trial name
- NCT00741455
- Testing
- Stem Cell Transplant, G-CSF, Fludarabine
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Sickle Cell Disease
A Study of the Effect of IW-1701 (Olinciguat), a Stimulator of Soluble Guanylate Cyclase (sGC), on Patients With Sickle Cell Disease (SCD)
The primary objective of the 1701-202 STRONG SCD study is to evaluate the safety and tolerability of different dose levels of IW-1701 compared with placebo when administered daily for approximately 12 weeks to patients with…
- Trial name
- STRONG SCD (NCT03285178)
- Testing
- IW-1701
- Where
- 37 sites in United States, Lebanon and 1 more
- Volunteers
- 88 people
- Sponsor
- Cyclerion Therapeutics
Anemia, Carcinoma, Non-Small-Cell Lung
To Determine Safe and Effective Dose of Sotatercept for the Treatment of Chemotherapy Induced Anemia in Participants With Advanced Non-small Cell Lung Cancer
The purpose of this study was to determine an effective and safe dose of sotatercept (ACE-011) for the treatment of chemotherapy-induced anemia (CIA) in participants with metastatic non-small cell lung cancer (NSCLC) who are…
- Conditions
- Anemia, Carcinoma, Non-Small-Cell Lung, Carcinoma, Small-Cell Lung, Bladder Cancer
- Trial name
- NCT01284348
- Testing
- Sotatercept 15 mg, Sotatercept 30 mg
- Volunteers
- 26 people
- Sponsor
- Merck Sharp & Dohme LLC
Acute Myeloid Leukemia
MEN1703 (SEL24) in Participants With Acute Myeloid Leukemia
The purpose of the clinical trial is to identify the maximum tolerated dose of MEN1703 and to further investigate its safety profile in participants with acute myeloid leukemia (AML).
- Trial name
- Diamond-01 (NCT03008187)
- Testing
- MEN1703
- Where
- 15 sites in United States, Italy and 2 more
- Volunteers
- 73 people
- Sponsor
- Menarini Group
Anemia
Study to Assess the Efficacy and Safety of HX575 in the Treatment of Chemotherapy Associated Anemia in Cancer Patients
This is a randomized, double-blind, multicenter clinical phase III study involving about 105 cancer patients aged >18 years who are receiving palliative chemotherapy and who are suffering from chemotherapy associated anemia.
- Trial name
- NCT00711958
- Testing
- HX575, solution for injection (s.c.), ERYPO®, Janssen-Cilag, solution for injection (s.c.)
- Where
- 19 sites in Germany, Romania
- Volunteers
- 114 people
- Sponsor
- Sandoz
Adult T-Cell Leukemia/Lymphoma, Anaplastic Large Cell Lymphoma, ALK-Negative
Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma
This phase II trial studies the side effects and how well brentuximab vedotin and combination chemotherapy work in treating patients with CD30-positive peripheral T-cell lymphoma.
- Conditions
- Adult T-Cell Leukemia/Lymphoma, Anaplastic Large Cell Lymphoma, ALK-Negative, Anaplastic Large Cell Lymphoma, ALK-Positive, Angioimmunoblastic T-Cell Lymphoma
- Trial name
- NCT03113500
- Testing
- Brentuximab Vedotin, Cyclophosphamide, Doxorubicin
- Where
- 5 sites in United States, Canada
- Volunteers
- 48 people
- Sponsor
- City of Hope Medical Center
Multiple Myeloma
Study of BTK Inhibitor, Ibrutinib in Combination With Carfilzomib in Subjects With Relapsed and Refractory Multiple Myeloma
A MULTICENTER PHASE 1/2B STUDY OF THE BRUTON'S TYROSINE KINASE INHIBITOR, IBRUTINIB (PCI-32765), IN COMBINATION WITH CARFILZOMIB (KYPROLIS™) IN SUBJECTS WITH RELAPSED OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA
- Trial name
- NCT01962792
- Testing
- Ibrutinib, Carfilzomib, Dexamethasone
- Where
- 17 sites in United States, Canada
- Volunteers
- 84 people
- Sponsor
- Pharmacyclics LLC.
DS Stage I Plasma Cell Myeloma, DS Stage II Plasma Cell Myeloma
Lenalidomide, Dexamethasone, and Clarithromycin in Treating Patients Who Have Undergone Stem Cell Transplant for Multiple Myeloma
This phase II trial studies lenalidomide, dexamethasone, and clarithromycin in treating patients who have undergone stem cell transplant for multiple myeloma.
- Conditions
- DS Stage I Plasma Cell Myeloma, DS Stage II Plasma Cell Myeloma, DS Stage III Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
- Trial name
- NCT00445692
- Testing
- Clarithromycin, Dexamethasone, Lenalidomide
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Fred Hutchinson Cancer Center
Multiple Myeloma
Trial of Three Stem Cell Mobilization Regimens for Multiple Myeloma
This phase III randomized trial compares three different peripheral stem cell mobilization regimens for patients with multiple myeloma who have received primary induction therapy or other therapies.
- Trial name
- NCT01146834
- Testing
- bortezomib (Velcade), cyclophosphamide, G-CSF
- Where
- 5 sites in United States
- Volunteers
- 47 people
- Sponsor
- Weill Medical College of Cornell University
Eosinophilic Esophagitis
A Study of Benralizumab in Patients With Eosinophilic Esophagitis
The aim of this Phase 3 study is to investigate the use of benralizumab as a treatment for patients with EoE. The effect of doses of benralizumab on EoE histologic signs and symptoms will be assessed over a 52-week treatment…
- Trial name
- MESSINA (NCT04543409)
- Testing
- Benralizumab
- Where
- 78 sites in United States, Canada and 10 more
- Volunteers
- 211 people
- Sponsor
- AstraZeneca
Myeloproliferative Disorders, Leukemia
Umbilical Cord Blood (UCB) Transplant, Fludarabine, Melphalan, and Anti-thymocyte Globulin (ATG) in Treating Patients With Hematologic Cancer
RATIONALE: Giving low doses of chemotherapy before a donor umbilical cord blood transplant helps stop the growth of cancer cells. It may also stop the patient's immune system from rejecting the donor's stem cells.
- Conditions
- Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00827099
- Testing
- anti-thymocyte globulin, fludarabine phosphate, Melphalan
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Northside Hospital, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.